New Statistics Canada research shows the full extent of the innovative pharmaceutical sector’s investments in Canada

April 12, 2021

Statistics Canada’s new report […]

Innovative Medicines Canada welcomes the Quebec budget’s emphasis on economic recovery, innovation and health

March 26, 2021

Ottawa, March 26, 2021 – Pamela Fralick, President of Innovative Medicines Canada (IMC), welcomes the Quebec budget’s emphasis on innovation, health, and economic recovery. “As a driving force for health research and […]

PMPRB misleading Canadians on the value of innovative medicines

March 25, 2021

We are disappointed by a number of misleading statements […]

Innovative Medicines Canada statement about treatment options for COVID-19 patients

March 8, 2021

Ottawa, March 8, 2021 – Innovative Medicines Canada (IMC) issued the following statement about treatment options for COVID-19 patients. “Since the pandemic began, there has been unprecedented collaboration across governments, academia, […]

Innovative Medicines Canada responds to calls for disclosure of proprietary business information

February 19, 2021

IMC issued the following statement in response to calls for the disclosure […]

Innovative Medicines Canada statement regarding EU export mechanism for COVID-19 vaccines

February 2, 2021

IMC issued the following statement […]

New IMC report shows impact of chronic disease and increased claims on private drug plans

January 13, 2021

Growth in chronic disease and increased drug claims […]

Delaying implementation of PMPRB’s Regulations an opportunity to protect patient access to medicines and vaccines

December 30, 2020

We support Health Canada’s decision to delay […]

IMC says there is still time for the federal government to put Canadian patients first by delaying the January 1, 2021 implementation of PMPRB’s Regulations and Guidelines

December 29, 2020

Ottawa, December 29, 2020 – Innovative Medicines Canada (IMC) issued the following statement today regarding the looming implementation of the Patented Medicines Prices Review Board’s (PMPRB’s) Final Regulations and Guidelines, […]

Still time for federal government to act to protect patient access to new medicines and vaccines before January 1, 2021 implementation of new PMPRB Regulations and Guidelines

December 21, 2020

Ottawa, December 21, 2020—Innovative Medicines Canada (IMC) issued the following statement today warning of the impact the Patented Medicines Prices Review Board’s (PMPRB’s) Final Regulations and Guidelines will have on […]